Stagman,
In answer to your question, CVac is equally or better suited to early diagnosis v's late. The point is that until FDA approval is given, PRR are limited to treating people in "final stages" as a last resort.
FDA approval will make PRR a choice to early diagnoised patients, recommended by their specialist doctor as a non invasive alternative treatment to kemo !!
An all good win win for both patient, doctor & PRR (& of course shareholders).
Stagman,In answer to your question, CVac is equally or better...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
39.0¢ |
Change
-0.005(1.27%) |
Mkt cap ! $569.8M | |||
| Open | High | Low | Value | Volume |
| 40.0¢ | 40.0¢ | 39.0¢ | $325.3K | 824.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 23 | 629379 | 39.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.5¢ | 323214 | 22 |
View Market Depth
| Last trade - 13.40pm 19/06/2024 (20 minute delay) ? |
| IMM (ASX) Chart |